Cargando…

The prognostic value of YAP1 on clinical outcomes in human cancers

Background: As an important downstream factor in the Hippo pathway, yes-associated protein 1(YAP1) has been detected to be elevated in various cancers and demonstrated to play a role in tumor development. Therefore, we evaluated by a meta-analysis the prognostic value of YAP1 in cancer patients. Res...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ying, Hou, Yanshen, Xu, Peng, Deng, Yujiao, Liu, Kang, Wang, Meng, Tian, Tian, Dai, Cong, Li, Na, Hao, Qian, Song, Dingli, Zhou, Ling hui, Dai, Zhijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814621/
https://www.ncbi.nlm.nih.gov/pubmed/31613226
http://dx.doi.org/10.18632/aging.102358
_version_ 1783463024260022272
author Wu, Ying
Hou, Yanshen
Xu, Peng
Deng, Yujiao
Liu, Kang
Wang, Meng
Tian, Tian
Dai, Cong
Li, Na
Hao, Qian
Song, Dingli
Zhou, Ling hui
Dai, Zhijun
author_facet Wu, Ying
Hou, Yanshen
Xu, Peng
Deng, Yujiao
Liu, Kang
Wang, Meng
Tian, Tian
Dai, Cong
Li, Na
Hao, Qian
Song, Dingli
Zhou, Ling hui
Dai, Zhijun
author_sort Wu, Ying
collection PubMed
description Background: As an important downstream factor in the Hippo pathway, yes-associated protein 1(YAP1) has been detected to be elevated in various cancers and demonstrated to play a role in tumor development. Therefore, we evaluated by a meta-analysis the prognostic value of YAP1 in cancer patients. Results: Sixty-eight studies with 8631 patients were identified. The results indicated that YAP1 overexpression predicted unfavorable patient prognosis in studies with overall survival (OS) (HR=1.76, 95%CI: 1.50-2.06, p<0.001) and disease-free survival (DFS) (HR=1.39, 95%CI: 1.22-1.59, p<0.001), as well as in studies with recurrence-free survival (RFS) (HR=2.38, 95%CI: 1.73-3.27, p<0.001), and disease-specific survival (DSS) (HR=2.04, 95%CI: 1.55-2.70, p<0.001). Meanwhile, YAP1 overexpression was also observed to be significantly associated with worse OS in GEPIA (HR=1.2, p<0.001). Conclusions: Overexpression of YAP1 showed great association with poorer prognosis in patients with various cancers, particularly liver cancer. Therefore, YAP1 might be an important prognostic marker and a novel target of cancer therapy. Methods: We searched for potential publications in several online databases and retrieved relevant data. Overall and subgroup analyses were performed. Begg’s and Egger’s tests were used to assess publication bias. Online dataset GEPIA was used to generate the survival curves and verify the prognostic role of YAP1 in patients with tumors.
format Online
Article
Text
id pubmed-6814621
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-68146212019-11-05 The prognostic value of YAP1 on clinical outcomes in human cancers Wu, Ying Hou, Yanshen Xu, Peng Deng, Yujiao Liu, Kang Wang, Meng Tian, Tian Dai, Cong Li, Na Hao, Qian Song, Dingli Zhou, Ling hui Dai, Zhijun Aging (Albany NY) Research Paper Background: As an important downstream factor in the Hippo pathway, yes-associated protein 1(YAP1) has been detected to be elevated in various cancers and demonstrated to play a role in tumor development. Therefore, we evaluated by a meta-analysis the prognostic value of YAP1 in cancer patients. Results: Sixty-eight studies with 8631 patients were identified. The results indicated that YAP1 overexpression predicted unfavorable patient prognosis in studies with overall survival (OS) (HR=1.76, 95%CI: 1.50-2.06, p<0.001) and disease-free survival (DFS) (HR=1.39, 95%CI: 1.22-1.59, p<0.001), as well as in studies with recurrence-free survival (RFS) (HR=2.38, 95%CI: 1.73-3.27, p<0.001), and disease-specific survival (DSS) (HR=2.04, 95%CI: 1.55-2.70, p<0.001). Meanwhile, YAP1 overexpression was also observed to be significantly associated with worse OS in GEPIA (HR=1.2, p<0.001). Conclusions: Overexpression of YAP1 showed great association with poorer prognosis in patients with various cancers, particularly liver cancer. Therefore, YAP1 might be an important prognostic marker and a novel target of cancer therapy. Methods: We searched for potential publications in several online databases and retrieved relevant data. Overall and subgroup analyses were performed. Begg’s and Egger’s tests were used to assess publication bias. Online dataset GEPIA was used to generate the survival curves and verify the prognostic role of YAP1 in patients with tumors. Impact Journals 2019-10-15 /pmc/articles/PMC6814621/ /pubmed/31613226 http://dx.doi.org/10.18632/aging.102358 Text en Copyright © 2019 Wu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Wu, Ying
Hou, Yanshen
Xu, Peng
Deng, Yujiao
Liu, Kang
Wang, Meng
Tian, Tian
Dai, Cong
Li, Na
Hao, Qian
Song, Dingli
Zhou, Ling hui
Dai, Zhijun
The prognostic value of YAP1 on clinical outcomes in human cancers
title The prognostic value of YAP1 on clinical outcomes in human cancers
title_full The prognostic value of YAP1 on clinical outcomes in human cancers
title_fullStr The prognostic value of YAP1 on clinical outcomes in human cancers
title_full_unstemmed The prognostic value of YAP1 on clinical outcomes in human cancers
title_short The prognostic value of YAP1 on clinical outcomes in human cancers
title_sort prognostic value of yap1 on clinical outcomes in human cancers
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814621/
https://www.ncbi.nlm.nih.gov/pubmed/31613226
http://dx.doi.org/10.18632/aging.102358
work_keys_str_mv AT wuying theprognosticvalueofyap1onclinicaloutcomesinhumancancers
AT houyanshen theprognosticvalueofyap1onclinicaloutcomesinhumancancers
AT xupeng theprognosticvalueofyap1onclinicaloutcomesinhumancancers
AT dengyujiao theprognosticvalueofyap1onclinicaloutcomesinhumancancers
AT liukang theprognosticvalueofyap1onclinicaloutcomesinhumancancers
AT wangmeng theprognosticvalueofyap1onclinicaloutcomesinhumancancers
AT tiantian theprognosticvalueofyap1onclinicaloutcomesinhumancancers
AT daicong theprognosticvalueofyap1onclinicaloutcomesinhumancancers
AT lina theprognosticvalueofyap1onclinicaloutcomesinhumancancers
AT haoqian theprognosticvalueofyap1onclinicaloutcomesinhumancancers
AT songdingli theprognosticvalueofyap1onclinicaloutcomesinhumancancers
AT zhoulinghui theprognosticvalueofyap1onclinicaloutcomesinhumancancers
AT daizhijun theprognosticvalueofyap1onclinicaloutcomesinhumancancers
AT wuying prognosticvalueofyap1onclinicaloutcomesinhumancancers
AT houyanshen prognosticvalueofyap1onclinicaloutcomesinhumancancers
AT xupeng prognosticvalueofyap1onclinicaloutcomesinhumancancers
AT dengyujiao prognosticvalueofyap1onclinicaloutcomesinhumancancers
AT liukang prognosticvalueofyap1onclinicaloutcomesinhumancancers
AT wangmeng prognosticvalueofyap1onclinicaloutcomesinhumancancers
AT tiantian prognosticvalueofyap1onclinicaloutcomesinhumancancers
AT daicong prognosticvalueofyap1onclinicaloutcomesinhumancancers
AT lina prognosticvalueofyap1onclinicaloutcomesinhumancancers
AT haoqian prognosticvalueofyap1onclinicaloutcomesinhumancancers
AT songdingli prognosticvalueofyap1onclinicaloutcomesinhumancancers
AT zhoulinghui prognosticvalueofyap1onclinicaloutcomesinhumancancers
AT daizhijun prognosticvalueofyap1onclinicaloutcomesinhumancancers